FAM127B Inhibitors

Chemical inhibitors of FAM127B function primarily through the interruption of cell cycle regulation by targeting cyclin-dependent kinases (CDKs), which are essential enzymes in cell cycle progression. Palbociclib, Ribociclib, and Abemaciclib specifically inhibit CDK4/6. This inhibition results in reduced phosphorylation of the retinoblastoma protein (Rb), a key protein that controls the cell cycle transition from the G1 phase to the S phase. Consequently, cells are unable to progress through the cell cycle, which effectively halts proliferation. By preventing the phosphorylation and subsequent inactivation of Rb, these inhibitors keep the cell in a state of cell cycle arrest, directly impeding the processes in which FAM127B is involved.

Other compounds, such as Dinaciclib, Flavopiridol, Milciclib, SNS-032, PHA-793887, AT7519, RGB-286638, PF-477736, R547, AZD5438, SCH727965, BMS-265246, and Seliciclib, exhibit broader CDK inhibitory profiles. These inhibitors target various CDKs beyond CDK4/6, including CDK1, CDK2, CDK5, CDK7, and CDK9. For example, Dinaciclib and Flavopiridol disrupt not only cell cycle control but also transcriptional regulation by inhibiting CDKs that play a role in RNA polymerase II activation. The inhibition of these CDKs can prevent the initiation of transcription, and thus, the expression of proteins necessary for cell cycle progression and cellular division. The collective action of these inhibitors serves to disrupt the normal cycling and division of cells by affecting different checkpoints and phases of the cell cycle, thereby impeding the functional role of FAM127B in cell proliferation.